ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

27 links0 made here, not in the record54 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06692491Study of PrecisionTreatment for Rare Tumoursin China Guided by PDO andNGSPeking University Shenzhen HosPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedDRUGSAlbumin-Bound PaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEpirubicinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundVinorelbineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundFluorouracilIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDurvalumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionSintilimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTislelizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCamrelizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundToripalimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSerplulimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundAdebrelimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundEnvafolimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundOsimertinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionAlectinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionVemurafenibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPamiparibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundPyrotinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundImatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPalbociclibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionSavolitinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundEntrectinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Albumin-Bound Paclitaxel

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Albumin-Bound Paclitaxel”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2EpirubicinClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 2VinorelbineClaude Opus 5.5BackgroundCurrent
Nov 2CisplatinClaude Opus 5.5BackgroundCurrent
Nov 2IrinotecanClaude Opus 5.5BackgroundCurrent
Nov 2FluorouracilClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · optionCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2DurvalumabClaude Opus 5.5Background · optionCurrent
Nov 2AtezolizumabClaude Opus 5.5Background · optionCurrent
Nov 2SintilimabClaude Opus 5.5BackgroundCurrent
Nov 2TislelizumabClaude Opus 5.5BackgroundCurrent
Nov 2CamrelizumabClaude Opus 5.5BackgroundCurrent
Nov 2ToripalimabClaude Opus 5.5BackgroundCurrent
Nov 2SerplulimabClaude Opus 5.5BackgroundCurrent
Nov 2AdebrelimabClaude Opus 5.5BackgroundCurrent
Nov 2EnvafolimabClaude Opus 5.5BackgroundCurrent
Nov 2OsimertinibClaude Opus 5.5Background · optionCurrent
Nov 2AlectinibClaude Opus 5.5Background · optionCurrent
Nov 2VemurafenibClaude Opus 5.5BackgroundCurrent
Nov 2PamiparibClaude Opus 5.5BackgroundCurrent
Nov 2PyrotinibClaude Opus 5.5BackgroundCurrent
Nov 2ImatinibClaude Opus 5.5BackgroundCurrent
Nov 2PalbociclibClaude Opus 5.5Background · optionCurrent
Nov 2SavolitinibClaude Opus 5.5BackgroundCurrent
Nov 2EntrectinibClaude Opus 5.5Background · optionCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18EpirubicinRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18VinorelbineRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18IrinotecanRule based · role ruleBackgroundAgrees
Nov 18FluorouracilRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18DurvalumabRule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees
Nov 18SintilimabRule based · role ruleTestedOverridden
Nov 18TislelizumabRule based · role ruleBackgroundAgrees
Nov 18CamrelizumabRule based · role ruleTestedOverridden
Nov 18ToripalimabRule based · role ruleBackgroundAgrees
Nov 18SerplulimabRule based · role ruleTestedOverridden
Nov 18AdebrelimabRule based · role ruleTestedOverridden
Nov 18EnvafolimabRule based · role ruleTestedOverridden
Nov 18OsimertinibRule based · role ruleBackgroundAgrees
Nov 18AlectinibRule based · role ruleBackgroundAgrees
Nov 18VemurafenibRule based · role ruleBackgroundAgrees
Nov 18PamiparibRule based · role ruleTestedOverridden
Nov 18PyrotinibRule based · role ruleTestedOverridden
Nov 18ImatinibRule based · role ruleBackgroundAgrees
Nov 18PalbociclibRule based · role ruleBackgroundAgrees
Nov 18SavolitinibRule based · role ruleTestedOverridden
Nov 18EntrectinibRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.